Stay updated with breaking news from Brucee Sands. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and
Already approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for Crohn's disease response and remission.
A long-term maintenance study suggested continuing mirikizumab for 104 weeks is safe and provides durable benefit in patients with active ulcerative colitis.
Celltrion today presented positive twoyear results from the extended LIBERTY studies LIBERTYCD1 and LIBERTYUC2 in patients with moderately to severely active Crohns disease CD and ulcerative colitis UC. Celltrion also presented endoscopic outcomes from the posthoc analysis of the LIBERTYCD study.3